Brussels, Belgium

Camille Locht

USPTO Granted Patents = 35 


 

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 155(Granted Patents)


Location History:

  • Wannehaing, FR (2000)
  • Wannehain, FR (1998 - 2005)
  • Lille Cedex, FR (2015)
  • Lille, FR (2016)
  • Brussels, BE (2010 - 2023)

Company Filing History:

goldMedal21 out of 55 
 
Institut Pasteur De Lille
 patents
silverMedal20 out of 1,743 
 
Institut National De La Sante Et De La Recherche Medicale
 patents
bronzeMedal5 out of 805 
 
National University of Singapore
 patents
43 out of 36 
 
Nationaluniversity of Ireland, Maynooth
 patents
51 out of 67 
 
Smithkline Beecham Biologicals S.a.
 patents
61 out of 7 
 
Smithkline Beecham Biologicals
 patents
71 out of 3 
 
Institute Pasteur De Lille
 patents
81 out of 93 
 
UniversitÉ Libre De Bruxelles
 patents
91 out of 1 
 
Universite Du Droit Et De La Sante De Lille Ii
 patent
101 out of 2 
 
Universite Droit Et Sante Lille Ii
 patents
111 out of 5,072 
 
Centre National De La Recherche Scientifique
 patents
121 out of 1 
 
Universite De Lille 2, Universite Du Droit Et De La Sante
 patent
131 out of 2 
 
Aeras
 patents
141 out of 1 
 
Unstitut National De La Sante Et De La Rechereche Medicale
 patent
158 out of 832,718 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...
Loading Chart...
Loading Chart...
35 patents (USPTO):Explore Patents

Title: Innovations in Allergy Treatment: The Contributions of Camille Locht

Introduction

Camille Locht is a prominent inventor based in Brussels, Belgium, renowned for his groundbreaking work in the field of immunology and vaccine development. With a remarkable portfolio of 34 patents, Locht has made significant strides in addressing allergen-driven airway pathologies, contributing to the advancement of therapeutic and prophylactic treatments.

Latest Patents

Among Locht's latest inventions is a live attenuated vaccine designed for the prophylaxis and treatment of allergen-driven airway pathologies. This innovative approach focuses on a vaccine deficient in critical toxins such as tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT). Additionally, he has developed a Fim3-producing BPZE1 derivative that demonstrates sufficiently stable fim3 expression, yielding improved protection in murine models against Fim3-only clinical isolates. Notably, this fim3 expression did not compromise the protective efficacy against Fim2+ strains or against strains producing neither Fim2 nor Fim3.

Career Highlights

Locht's career is marked by his association with prestigious institutions, including the Institut Pasteur de Lille. His extensive work in vaccine innovation has positioned him as a leader in his field, particularly in developing strategies targeting airway-related allergies.

Collaborations

Throughout his career, Locht has collaborated with talented individuals, including Nathalie Mielcarek and Anne-Sophie Debrie. These partnerships have enriched his research initiatives and fostered advancements in the realm of allergy treatment.

Conclusion

Camille Locht's contributions to the field of immunology and vaccine development are commendable. With a robust portfolio of patents and a commitment to innovation, Locht continues to pave the way for effective treatments for allergen-driven airway diseases, underscoring his role as an influential inventor in the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…